Homology Medicines, Inc. priced its IPO of 9 million common shares at $16 per share.

The Bedford, Mass.-based genetic medicines company granted the underwriters an option to buy up to an additional 1,350,000 shares.

Homology's common stock is expected to start trading on the Nasdaq Global Select Market on March 28 under the ticker symbol FIXX.

Bank of America Merrill Lynch, Cowen and Evercore ISI are acting as joint book-running managers, while BTIG is acting as the lead manager for the offering.